Filtered By:
Condition: Atrial Fibrillation
Countries: Spain Health
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 92 results found since Jan 2013.
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
CONCLUSIONS: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding.PMID:36200548 | DOI:10.5603/CJ.a2022.0091
Source: Cardiology Journal - October 6, 2022 Category: Cardiology Authors: Manuel Anguita S ánchez Francisco Mar ín Jaime Masjuan Juan Cos ín-Sales Jos é Manuel Vázquez Rodríguez Vivencio Barrios Gonzalo Bar ón-Esquivias I ñaki Lekuona Alejandro I P érez-Cabeza Rom án Freixa-Pamias Francisco Javier Parra Jimenez Mohame Source Type: research
Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries
Conclusion: Despite the fact that rivaroxaban is prescribed for elderly patients with a high thromboembolic risk, rates of outcomes remain low.PMID:36148923 | DOI:10.2217/cer-2022-0111
Source: Journal of Comparative Effectiveness Research - September 23, 2022 Category: General Medicine Authors: Francisco Marin Marcelo Sanmart ín Fernández I ñaki Lekuona Fernando Arribas Gonzalo Bar ón-Esquivias Vivencio Barrios Juan Cosin-Sales Rom án Freixa-Pamias Jaime Masjuan Alejandro I P érez-Cabeza Vanessa Rold án Schilling Jos é Manuel Vázquez Ro Source Type: research
